Literature DB >> 30701958

Ligand-Efficient Inhibitors of Trichomonas vaginalis Adenosine/Guanosine Preferring Nucleoside Ribohydrolase.

Samantha N Muellers1, Juliana A Gonzalez1, Abinash Kaur1, Vital Sapojnikov1, Annie Laurie Benzie1, Dean G Brown2, David W Parkin1, Brian J Stockman1.   

Abstract

Trichomoniasis is caused by the parasitic protozoan Trichomonas vaginalis and is the most prevalent, nonviral sexually transmitted disease. The parasite has shown increasing resistance to the current 5-nitroimidazole therapies indicating the need for new therapies with different mechanisms. T. vaginalis is an obligate parasite that scavenges nucleosides from host cells and then uses salvage pathway enzymes to obtain the nucleobases. The adenosine/guanosine preferring nucleoside ribohydrolase was screened against a 2000-compound diversity fragment library using a 1H NMR-based activity assay. Three classes of inhibitors with more than five representatives were identified: bis-aryl phenols, amino bicyclic pyrimidines, and aryl acetamides. Among the active fragments were 10 compounds with ligand efficiency values greater than 0.5, including five with IC50 values <10 μM. Jump-dilution and detergent counter screens validated reversible, target-specific activity. The data reveals an emerging SAR that is guiding our medicinal chemistry efforts aimed at discovering compounds with nanomolar potency.

Entities:  

Keywords:  Trichomonas vaginalis; antitrichomonal therapeutics; fragment screening; nucleoside ribohydrolase

Mesh:

Substances:

Year:  2019        PMID: 30701958      PMCID: PMC6544043          DOI: 10.1021/acsinfecdis.8b00346

Source DB:  PubMed          Journal:  ACS Infect Dis        ISSN: 2373-8227            Impact factor:   5.084


  23 in total

1.  Fragment-based drug design: how big is too big?

Authors:  Philip J Hajduk
Journal:  J Med Chem       Date:  2006-11-30       Impact factor: 7.446

2.  Compound aggregation in drug discovery: implementing a practical NMR assay for medicinal chemists.

Authors:  Steven R LaPlante; Rebekah Carson; James Gillard; Norman Aubry; René Coulombe; Sylvain Bordeleau; Pierre Bonneau; Michael Little; Jeff O'Meara; Pierre L Beaulieu
Journal:  J Med Chem       Date:  2013-06-13       Impact factor: 7.446

3.  Identification of proton-pump inhibitor drugs that inhibit Trichomonas vaginalis uridine nucleoside ribohydrolase.

Authors:  Tara A Shea; Paola J Burburan; Vivian N Matubia; Sandy S Ramcharan; Irving Rosario; David W Parkin; Brian J Stockman
Journal:  Bioorg Med Chem Lett       Date:  2014-01-13       Impact factor: 2.823

Review 4.  Strategies for Prevention and Treatment of Trichomonas vaginalis Infections.

Authors:  Kawthar Bouchemal; Christian Bories; Philippe M Loiseau
Journal:  Clin Microbiol Rev       Date:  2017-07       Impact factor: 26.132

5.  Impact of enzyme concentration and residence time on apparent activity recovery in jump dilution analysis.

Authors:  Robert A Copeland; Aravind Basavapathruni; Mikel Moyer; Margaret Porter Scott
Journal:  Anal Biochem       Date:  2011-05-27       Impact factor: 3.365

6.  Design and synthesis of aza-flavones as a new class of xanthine oxidase inhibitors.

Authors:  Rajni Dhiman; Sahil Sharma; Gagandip Singh; Kunal Nepali; Preet Mohinder Singh Bedi
Journal:  Arch Pharm (Weinheim)       Date:  2012-10-18       Impact factor: 3.751

Review 7.  Getting trichy: tools and approaches to interrogating Trichomonas vaginalis in a post-genome world.

Authors:  Melissa D Conrad; Martina Bradic; Sally D Warring; Andrew W Gorman; Jane M Carlton
Journal:  Trends Parasitol       Date:  2012-12-05

8.  Draft genome sequence of the sexually transmitted pathogen Trichomonas vaginalis.

Authors:  Jane M Carlton; Robert P Hirt; Joana C Silva; Arthur L Delcher; Michael Schatz; Qi Zhao; Jennifer R Wortman; Shelby L Bidwell; U Cecilia M Alsmark; Sébastien Besteiro; Thomas Sicheritz-Ponten; Christophe J Noel; Joel B Dacks; Peter G Foster; Cedric Simillion; Yves Van de Peer; Diego Miranda-Saavedra; Geoffrey J Barton; Gareth D Westrop; Sylke Müller; Daniele Dessi; Pier Luigi Fiori; Qinghu Ren; Ian Paulsen; Hanbang Zhang; Felix D Bastida-Corcuera; Augusto Simoes-Barbosa; Mark T Brown; Richard D Hayes; Mandira Mukherjee; Cheryl Y Okumura; Rachel Schneider; Alias J Smith; Stepanka Vanacova; Maria Villalvazo; Brian J Haas; Mihaela Pertea; Tamara V Feldblyum; Terry R Utterback; Chung-Li Shu; Kazutoyo Osoegawa; Pieter J de Jong; Ivan Hrdy; Lenka Horvathova; Zuzana Zubacova; Pavel Dolezal; Shehre-Banoo Malik; John M Logsdon; Katrin Henze; Arti Gupta; Ching C Wang; Rebecca L Dunne; Jacqueline A Upcroft; Peter Upcroft; Owen White; Steven L Salzberg; Petrus Tang; Cheng-Hsun Chiu; Ying-Shiung Lee; T Martin Embley; Graham H Coombs; Jeremy C Mottram; Jan Tachezy; Claire M Fraser-Liggett; Patricia J Johnson
Journal:  Science       Date:  2007-01-12       Impact factor: 47.728

9.  The Ecstasy and Agony of Assay Interference Compounds.

Authors:  Courtney Aldrich; Carolyn Bertozzi; Gunda I Georg; Laura Kiessling; Craig Lindsley; Dennis Liotta; Kenneth M Merz; Alanna Schepartz; Shaomeng Wang
Journal:  ACS Cent Sci       Date:  2017-02-28       Impact factor: 14.553

Review 10.  Trichomonas vaginalis: a review of epidemiologic, clinical and treatment issues.

Authors:  Patricia Kissinger
Journal:  BMC Infect Dis       Date:  2015-08-05       Impact factor: 3.090

View more
  4 in total

1.  NMR-Based Activity Assays for Determining Compound Inhibition, IC50 Values, Artifactual Activity, and Whole-Cell Activity of Nucleoside Ribohydrolases.

Authors:  Brian J Stockman; Abinash Kaur; Julia K Persaud; Maham Mahmood; Samantha F Thuilot; Melissa B Emilcar; Madison Canestrari; Juliana A Gonzalez; Shannon Auletta; Vital Sapojnikov; Wagma Caravan; Samantha N Muellers
Journal:  J Vis Exp       Date:  2019-06-30       Impact factor: 1.355

2.  Discovery of Ligand-Efficient Scaffolds for the Design of Novel Trichomonas vaginalis Uridine Nucleoside Ribohydrolase Inhibitors Using Fragment Screening.

Authors:  Shannon Auletta; Wagma Caravan; Julia K Persaud; Samantha F Thuilot; Dean G Brown; David W Parkin; Brian J Stockman
Journal:  ACS Omega       Date:  2019-09-16

Review 3.  Structure, Oligomerization and Activity Modulation in N-Ribohydrolases.

Authors:  Massimo Degano
Journal:  Int J Mol Sci       Date:  2022-02-25       Impact factor: 5.923

4.  Clinical Effect of Metronidazole Vaginal Effervescent Tablet Combined with Flavescentis Sophora Suppository in the Treatment of Trichomonas Vaginitis.

Authors:  Lingjia Shi; Dan Yang; Xin Wang
Journal:  Contrast Media Mol Imaging       Date:  2022-08-04       Impact factor: 3.009

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.